An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without "olsalazine"

Journal of Crohn's and Colitis

Volumn 2, Issue 4, 2008, Pages 296-303

  Abdin, Amany A ^a   Saeid, Eman M ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Lactobacillus acidophilus; Olsalazine; Probiotics; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; OLSALAZINE; OXAZOLONE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; LACTOBACILLUS ACIDOPHILUS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 56549113899     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.04.002     Document Type: Article

References (68)

1. Martins N.B., and Peppercorn M.A. Inflammatory bowel disease. Am J Manag Care 10 (2004) 544-552
2. Lukas M., Bortlik M., and Maratka Z. What is the origin of ulcerative colitis? Still more questions than answers. Postgrad Med J 82 (2006) 620-625
3. Yamamoto-Furusho J.K. Innovative therapeutics for inflammatory bowel disease. World J Gastroenterol 13 13 (2007) 1893-1896
4. Head K.A., and Jurenka J.S. Inflammatory bowel disease part I: ulcerative colitis - pathophysiology and conventional and alternative treatment options. Altern Med Rev 8 3 (2003) 247-283
5. Singer M.V., Schmausser H., and Schönfeld G. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis-results of a field study. Hepatogastroenterology 53 69 (2006) 317-321
6. Stein R.B., and Hanauer S.B. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 23 5 (2000) 429-448
7. Kles K.A., Vavricka S.R., Turner J.R., Musch M.W., Hanauer S.B., and Chang E.B. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis 11 3 (2005) 253-257
8. Cui H.H., Chen C.L., Wang J.D., et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 10 10 (2004) 1521-1525
9. Tamboli C.P., Neut C., Desremeaux P., and Colombel J.F. Dysbiosis in inflammatory bowel disease. Gut 53 (2004) 1-4
10. Farrell R.J., and LaMont J.T. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 31 (2002) 41-62
11. Fuller R. A review: probiotics in man and animals. J Appl Bacteriol 66 (1989) 365-378
12. FAO/WHO. Report of a Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. World Health Organization and Food and Agriculture Organization of the United Nations, London, Ontario, Canada (2001)
13. Dunne C., O'Mahony L., Murphy L., et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings1,2,3,4. Am J Clin Nutr 73 2 (2001) 386S-392s
14. Rioux K.P., and Fedorak R.N. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 40 3 (2006) 260-263
15. Boirivant M., Fuss I.J., Chu A., and Strober W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin-4. J Exp Med 188 10 (1998) 1929-1939
16. Moorthy G., Murali M.R., and Devaraj S.N. Protective role of lactobacilli in Shigella dysenteriae 1-induced diarrhea in rats. Nutrition 23 5 (2007) 424-433
17. Davis A.E., Patterson F., and Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br J Cancer 68 5 (1993) 1043-1044
18. Modzelewski B., and Janiak A. Pentoxiyphilline as a cyclooxygenase (COX-2) inhibitor in experimental sepsis. Med Sci Monit 10 7 (2004) BR233-BR237
19. Zhang L., Yu J., Li D., Huang Y., Chen Z., and Wang X. Effects of cytokines on carbon tetrachloride-induced hepatic fibrogenesis in rats. World J Gastroenterol 10 1 (2004) 77-81
20. Cooper H.S., Murthy S.N., Shah R.S., and Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69 2 (1993) 238-249
21. Gastrointestinal tract:large bowel:colitis:ulcerative colitis. In: Rosai J. (Ed). Rosai and Ackerman's Surgical Pathology. 9th edition (2004), Mosby 782-788 Chapter 11
22. Elson C.O., Sartor R.B., Tennyson G.S., and Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 109 (1995) 1344-1367
23. Strober W., Fuss I.J., and Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 20 (2002) 495-549
24. Hibi T., Ogata H., and Sakuraba A. Animal models of inflammatory bowel disease. J Gastroenterol 37 (2002) 409-417
25. Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., and Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17 5 (2002) 629-638
26. Kojima R., Kuroda S., Ohkishi T., Nakamaru K., and Hatakeyama S. Oxazolone-induced colitis in balb/c mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. J Pharmacol Sci 96 (2004) 307-313
27. Fiorentino D.F., Bond M.W., and Mosmann T.R. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med 170 (1989) 2081-2095
28. Furrie E., Macfarlane S., Kennedy A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54 (2005) 242-249
29. MacDonald T.T., and Murch S.H. Aetiology and pathogenesis of chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 8 (1994) 1-34
30. Zheng P., Niu F., Liu W., Shi Y., and Lu L. Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats. World J Gastroenterol 11 31 (2005) 4912-4915
31. Sands B.E., and Kaplan G.G. The role of TNF{alpha} in ulcerative colitis. J Clin Pharmacol 47 8 (2007) 930-941
32. Bai A.P., and Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med J 82 (2006) 376-382
33. Bruewer M., Luegering A., Kucharzik T., et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171 (2003) 6164-6172
34. Umehara Y., Kudo M., Nakaoka R., Kawasaki T., and Shiomi M. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology 53 72 (2006) 879-882
35. Goral V., Celenk T., Kaplan A., and Sit D. Plasma cytokine levels in ulcerative colitis. Hepatogastroenterology 54 76 (2007) 1130-1133
36. Quigley E.M. Probiotics in the management of colonic disorders. Curr Gastroenterol Rep 9 5 (2007) 434-440
37. Perdigón G., Maldonado Galdeano C., Valdez J.C., and Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 56 Suppl 4 (2002) S21-S26
38. Daniel C., Poiret S., Goudercourt D., Dennin V., Leyer G., and Pot B. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. Appl Environ Microbiol 72 9 (2006) 5799-5805
39. Gill H.S., and Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 80 (2004) 516-526
40. Shah N.P. Probiotic bacteria: selective enumeration and survival in dairy foods. J Dairy Sci 83 (2000) 894-907
41. Galdeano C.M., and Perdigón G. Role of viability of probiotic strains in their persistence in the gut and in mucosal immune stimulation. J Appl Microbiol 97 (2004) 673-681
42. Perdigón G., Galdeano C.M., Vinderola C.G., de Moreno A., Medici M., and Bibas Bonet M.E. Immunomodulation of mucosal immune response by probiotics. Curr Trends Immunol 6 (2005) 69-85
43. Galdeano C.M., de Moreno de LeBlanc A.M., Vinderola G., Bonet M.E., and Perdigón G. Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. Clin Vaccine Immunol 14 5 (2007) 485-492
44. Borruel N., Carol M., Casellas F., et al. Increased mucosal production TNF-in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51 (2002) 659-664
45. Bernet M.F., Brassart D., Neeser J.R., and Servin A.L. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 35 (1994) 483-489
46. Babakissa C., Colomb V., Andrieux C., et al. Luminal fermentation and colonocyte metabolism in a rat model of enteral nutrition. Dig Dis Sci 48 (2003) 1339-1345
47. Yan F., and Polk D.B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 277 (2002) 50959-50965
48. Sheil B., Shanahan F., and O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr 137 (2007) 819S-824S
49. Shah N.P., Lankaputhra W.E.V., Britz M., and Kyle W.S.A. Survival of L. acidophilus and Bifidobacterium bifidum in commercial yoghurt during refrigerated storage. Int Dairy J 5 (1995) 515-521
50. Hood S.K., and Zottola M.L. Effect of low pH on the ability of Lactobacillus acidophilus to survive and adhere to human intestinal cells. J Food Sci 53 (1988) 1514-1516
51. Shah N.P., and Jelen P. Survival of lactic acid bacteria and their lactases under acidic conditions. J Food Sci 55 (1990) 506-509
52. Lankaputhra W.E.V., and Shah N.P. Investigation of factors affecting viability of Lactobacillus acidophilus and bifidobacteria in yoghurt. 24th Int Dairy Congress, Melbourne, Australia (1994) 292
53. Young C.K., and Nelson F.E. Survival of Lactobacillus acidophilus in 'sweet acidophilus milk' during refrigerated storage. J Food Prot 41 (1978) 248-250
54. Bertoni J., Calamary L., Maiamti M.G., and Azzoni A. Factors modifying the acidification rate of milk. Lait 17 (1994) 941-943
55. Guslandi M., Giollo P., and Testoni P.A. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15 6 (2003) 697-698
56. Tursi A., Brandimarte G., Giorgetti G.M., Forti G., Modeo M.E., and Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10 11 (2004) PI126-PI131
57. Tursi A., Brandimarte G., Giorgetti G.M., and Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 40 4 (2006) 312-316
58. Zocco M.A., dal Verme L.Z., Cremonini F., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23 11 (2006) 1567-1574
59. Jiang X.L., and Cui H.F. Different therapy for different types of ulcerative colitis in China. World J Gastroenterol 10 10 (2004) 1513-1520
60. Truelove S.C. Evolution of olsalazine. Scand J Gastroenterol 23 suppl 148 (1988) 3-6
61. Altman D.F. Drugs used in gastrointestinal diseases. In: Katzung B.G. (Ed). Basic & clinical pharmacology. 7th edition (1998), Appleton & Lang 1017-1029
62. Campbell D.E., and Berglindh T. Pharmacology of olsalazine. Scand J Gastroenterol Suppl. 148 (1988) 7-12
63. Ryde E.M., and Ahnfelt N.O. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur J Clin Pharmacol 34 (1988) 481-488
64. Wadworth A.N., and Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in inflammatory bowel disease. Drugs 41 (1991) 647-664
65. Gionchetti P., Campieri M., Venturi A., et al. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Aliment Pharmacol Ther 10 4 (1996) 601-605
66. Støa-Birketvedt G., and Florholmen J. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Aliment Pharmacol Ther 13 3 (1999) 357-361
67. Travis S.P., Tysk C., de Silva H.J., Sandberg-Gertzén H., Jewell D.P., and Järnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 35 9 (1994) 1282-1286
68. Meyers S., Sachar D.B., Present D.H., and Janowitz H.D. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose ranging clinical trial. Gastroenterology 93 (1987) 1255-1262